Atglistatin
ATGL inhibitor / Atglistatin is the first small molecule inhibitor of adipose triglyceride lipase (ATGL) – IC50 = 700 nM.1 It exhibits high selectivity for ATGL, is active in vitro and in vivo, and does not inhibit other key metabolic lipases. ATGL is the rate limiting enzyme in lipolysis and is thus an excellent target to reduce fatty acid mobilization and decrease lipotoxicity in metabolic syndrome. Inhibition of ATGL may be a useful strategy to attack the increased metabolic rate of cancerous cells.2
Biochemicals & reagents
1469924-27-3
1) Mayer et al. (2013), Development of small-molecule inhibitors targeting adipose triglyceride lipase; Nat. Chem. Biol. 9 785 2) Zagani et al. (2015) Inhibition of adipose triglyceride lipase (ATGL) by the putative tumor suppressor G0S2 or a small molecule inhibitor attenuates the growth of cancer cells; Oncotarget 6 28282
-20°C
TARGET: Lipase -- PATHWAY: Fatty acid metabolism -- DISEASE AREA: Cancer; Obesity